ARTICLE | Company News

Therion deal

November 7, 1994 8:00 AM UTC

Therion will generate vaccine candidates based on live recombinant poxvirus vectors that express specific tumor-associated antigens characterized by the National Cancer Institute.

Under the five-year CRADA, the collaborators will conduct preclinical studies of product candidates. NCI will be responsible for Phase I and II trials. ...